Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma

Neuro-Oncology

Volumn 18, Issue 3, 2016, Pages 361-367

  Baraniskin, Alexander ^a   Zaslavska, Elena ^a   Nöpel Dünnebacke, Stefanie ^a   Ahle, Guido ^b   Seidel, Sabine ^a   Schlegel, Uwe ^a   Schmiegel, Wolff ^a   Hahn, Stephan ^a   Schroers, Roland ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Hôpitaux Civils de Colmar   (France)

Author keywords

cerebrospinal fluid (CSF); disease course; primary central nervous system lymphoma; small nuclear RNA (snRNA)

Indexed keywords

MICRORNA 21; SMALL NUCLEAR RNA; TUMOR MARKER; U2 SMALL NUCLEAR RNA FRAGMENT; UNCLASSIFIED DRUG; MICRORNA; U2 SMALL NUCLEAR RNA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CEREBROSPINAL FLUID EXAMINATION; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA STABILITY; SENSITIVITY AND SPECIFICITY; BLOOD; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE COURSE; GENETICS; LUNG NEOPLASMS; LYMPHOMA; MIDDLE AGED; PROCEDURES; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOMA; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL NUCLEAR;

EID: 84960104110     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov144     Document Type: Article

References (26)

1. Baraniskin A, Deckert M, Schulte-Altedorneburg G, et al. Current strategies in the diagnosis of diffuse large B-cell lymphoma of the central nervous system. Br J Haematol. 2012;156(4):421-432.
2. Shenkier TN, Blay JY, O'Neill BP, et al. Primary CNS lymphoma of T-cell origin: A descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol. 2005; 23:2233-2239.
3. Juergens A, Pels H, Rogowski S, et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol. 2010;67:182-189.
4. Korfel A, Schlegel U. Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol. 2013;9:317-327.
5. Carninci P, Kasukawa T, Katayama S, et al. RIKEN Genome Exploration Research Group and Genome Science Group. The transcriptional landscape of the mammalian genome. Science. 2005;309(5740):1559-1563.
6. Friedman JM, Jones PA. MicroRNAs: critical mediators of differentiation, development and disease. Swiss Med Wkly. 2009; 139(33-34):466-472.
7. Zarate R, Boni V, Bandres E, et al. MiRNAs and LincRNAs: Could they be considered as biomarkers in colorectal cancer? Int J Mol Sci. 2012;13(1):840-865.
8. Day JR, Jost M, Reynolds MA, et al. PCA3: from basic molecular science to the clinical lab. Cancer Lett. 2011;301(1):1-6.
9. Baraniskin A, Kuhnhenn J, Schlegel U, et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011;117(11):3140-3146.
10. Baraniskin A, Kuhnhenn J, Schlegel U, et al. Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro Oncol. 2012;14(1):29-33.
11. Baraniskin A, Kuhnhenn J, Schlegel U, et al. MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma. J Neurooncol. 2012;109(2):239-244.
12. Baraniskin A, Nöpel-Dünnebacke S, Ahrens M, et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. Int J Cancer. 2013; 132(2):E48-E57.
13. Baraniskin A, Nöpel-Dünnebacke S, Schumacher B, et al. Analysis of U2 small nuclear RNA fragments in the bile differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Dig Dis Sci. 2014;59(7):1436-1441.
14. Will CL, Lührmann R. Spliceosomal UsnRNP biogenesis, structure and function. Curr Opin Cell Biol. 2001;13(3):290-301.
15. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034-5043.
16. van Persijn van Meerten EL, Gelderblom H. RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol. 2010;20(6):1456-1467.
17. Ruijter JM, Ramakers C, Hoogaars WMH, et al. Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res. 2009;37(6):e45.
18. Pels H, Schmidt-Wolf IG, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21(24):4489-4495.
19. Jones CI, Zabolotskaya MV, King AJ, et al. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer. 2012;107:987-996.
20. Mazieres J, Catherinne C, Delfour O, et al. Alternative processing of the U2 small nuclear RNA produces a 19-22nt fragment with relevance for the detection of non-small cell lung cancer in human serum. PLoS One. 2013;8:e60134.
21. Takeshita N, Hoshino I, Mori M, et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer. 2013;108: 644-652.
22. Kuhlmann JD, Baraniskin A, Hahn SA, et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer. Clin Chem. 2014;60(1):206-213.
23. Pospisil V, Mocikova H, Jankovska M, et al. MicroRNA Analysis in the Cerebrospinal Fluid and Blood Serum of Lymphoma Patients At Diagnosis and in Response to Therapy. Blood (ASH Annual Meeting Abstracts). 2011;118(21):3663.
24. Pospisil V, Mocikova H, Klanova M, et al. Oncogenic Micrornas In Cerebrospinal Fluid and Sera Reflect Therapy Efficacy and Their Reappearance Precedes Clinical Relapse In Primary and Secondary CNS Lymphoma. Blood (ASH Annual Meeting Abstracts). 2013;122(21):177.
25. Mao X, Sun Y, Tang J. Serum miR-21 is a diagnostic and prognostic marker of primary central nervous system lymphoma. Neurol Sci. 2014;35(2):233-238.
26. Roth P, Keller A, Hoheisel JD, et al. Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients. Eur J Cancer. 2015;51(3):382-390.